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The APOBEC3 cytidine deami-nases play an important role in 
innate immunity but have also emerged 
as mediators of somatic mutations in 
human cancer. We recently reported a 
high incidence of APOBEC-mediated 
driver mutations in human papilloma-
virus-associated cancer, suggesting a key 
role for these enzymes in the develop-
ment of such tumors.
The apolipoprotein-B mRNA editing 
catalytic polypeptide like (APOBEC) fam-
ily of enzymes catalyze the deamination of 
cytosine bases, resulting in their conver-
sion to uracil. In humans the APOBEC3 
gene cluster on chromosome 22 encodes 
7 enzymes (A3A, B, C, D/E, F, G, and 
H) capable of deaminating cytosines in 
single-stranded (ss) DNA. Much of our 
knowledge of A3 gene function has come 
from studies of A3G hypermutation of 
HIV cDNA, an innate immune defense. 
However, a number of recent studies 
have suggested that certain A3 enzymes 
can display an off-target activity leading 
to somatic mutations in cancer. Work 
by Stratton and colleagues analyzing the 
nature and sequence context of muta-
tions to identify the mutational processes 
operating in different cancers uncovered a 
particular signature of long clusters of the 
point mutations TC > TT or TC > TG 
on the same strand, which they called 
“kataegis,” the Greek for thunderstorm. 
These mutation showers are likely caused 
by activity of a subset of the A3 enzymes 
that preferentially target cytosines follow-
ing a thymine,1 with the resulting uracil 
then undergoing transversion to guanine 
or transition to thymine.
Around the same time, Harris and col-
leagues showed using functional studies in 
cell lines and data from clinical samples, 
that one such ‘TC-specific’ A3 (A3B), is 
frequently overexpressed in breast cancer 
(BRCA) and that it is likely responsible 
for many of the cytidine mutations seen 
in these tumors.2 This discovery was fol-
lowed by widespread screens for evidence 
of A3 activity in cancer exome sequences 
from The Cancer Genome Atlas (TCGA) 
project and others.3,4 Several cancer types, 
notably cervical squamous cell carcinoma 
(CESC), bladder urothelial carcinoma 
(BLCA), and head and neck squamous 
cell carcinoma (HNSC), show a particu-
larly strong enrichment for these signature 
mutations. Noting that the majority of 
CESCs are associated with human pap-
illomavirus (HPV) and that A3 enzymes 
have previously been implicated in hype-
rediting of HPV DNA in premalignant 
cervical lesions,5 we hypothesized that this 
mutational process may play a particu-
larly important role in the development 
of HPV-associated cancers. We set out 
to test this by analyzing HNSC, a tumor 
type for which sequence data were avail-
able for sufficient numbers of both HPV+ 
and HPV− samples to permit a compara-
tive analysis.6
We used a variety of metrics to compare 
the extent of A3-mediated mutagenesis 
in the HPV+ and HPV− HNSC samples, 
including extraction of mutational sig-
natures and calculating the prevalence of 
TCW (TpCpA/T) > TTW and TCW 
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> TGW mutations in each sample.4,7 
Each metric by which we could assess 
A3-mediated mutation showed enrich-
ment with HPV positivity.
Compelling evidence for the involve-
ment of A3 enzymes in the pathogenesis 
of HPV+ tumors came from examining 
the genes that are mutated at TCW sites. 
We found that specific hotspot mutations 
in the PIK3CA proto-oncogene are of the 
TCW type and that PIK3CA is exclusively 
mutated at these sites in tumors displaying 
strong exome-wide enrichment for TCW 
mutations (HPV+ HNSC, CESC, and 
BLCA).
A number of questions arise from our 
findings: Does HPV infection or viral 
oncogene expression actively drive A3 
hypermutation of cellular DNA, or is 
there simply a dearth of other mutational 
processes in these tumors? What is caus-
ing the relatively high level of A3 muta-
tions in BLCA? HPV has been linked with 
BLCA but a recent comprehensive analysis 
of viral transcripts in tumor samples sug-
gests that HPV is present in only a very 
small fraction of BLCA.8 Whether tran-
sient infections might occasionally initiate 
tumorigenesis by activating APOBECs is 
a fascinating question.
Figure 1. the transition transversion mutational balance. ternary plots displaying the percentage balance between tCw > ttw transitions, tCw > 
tGw transversions, and all other point mutations in hPV− hNsC, hPV+ hNsC, and CesC. hNsC, head and neck squamous cell carcinoma; CesC, cervical 
squamous cell carcinoma.
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One striking feature of TCW muta-
tions that we observed is their close rela-
tionship with the number of non-TCW 
point mutations. Furano and colleagues 
recently demonstrated that ssDNA that is 
exposed during repair of mismatches can 
be mutated by TC-specific A3 enzymes.9 
This process occurs when base exci-
sion repair (BER) becomes coupled to a 
non-canonical mismatch repair (MMR) 
process, a pathway integral to activation-
induced cytidine deaminase (AID)-
dependent somatic hypermutation in 
lymphocytes. In such cases, repair of mis-
matches may expose extended stretches 
of ssDNA to A3 activity, offering a pos-
sible explanation for the strong correlation 
between TCW and other mutations.
Alternatively, the relative abundance of 
transitions and transversions at TCW sites 
can reveal the pathway by which deami-
nated cytosines are processed in a given 
tumor type.10 Evidence from DNA repair 
models in yeast suggest that C > G trans-
versions result largely from BER whereas 
C > T transitions may result from error 
prone DNA translesion synthesis during 
replication. When TCW > TGW, TCW 
> TTW and all other point mutations 
in HPV+ HNSC and CESC and HPV− 
HNSC are represented on ternary plots 
(Fig. 1) the increased fraction of C > T 
and C > G mutations at vulnerable sites 
in the HPV+ tumors is clear. Furthermore, 
in the HPV− tumors, TCW mutations 
are more often of the C > G type, sug-
gesting that BER may be more active in 
these cells, whereas both HPV+ HNSC 
and CESC are particularly enriched for 
transitions, potentially indicating replica-
tion across uracil without repair in HPV+ 
tumors (Fig. 1; ref. 6).
In conclusion, although studies from 
multiple groups point to a role for A3 
enzymes in the generation of somatic 
mutations in cancer, our work suggests 
that this process is particularly important 
in the development of HPV-associated 
tumors. Whether HPV infection induces 
A3 activity, or whether these tumors 
share common features with other cancers 
that are enriched for A3-driven muta-
tions, such as defects in certain DNA 
repair pathways for instance, is currently 
unclear. Determining the answers to such 
questions will hopefully give insight into 
which patients are most likely to develop 
cancer following HPV infection and 
potentially open up new avenues for DNA 
cytotoxic therapy.
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